Tradestie Institutional Equity Comparison Engine

BU vs ABVC โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ABVC Overall Edge

ABVC Captures Institutional Edge (1โ€“1 Pillars ยท 7โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to ABVC BioPharma, Inc. Common Stock (ABVC) driven by superior Growth & Margin while BU counters with relative strength in Momentum & Technical. Fundamentally, BU trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus ABVC at N/M Forward P/E and 0.0% operating margin (+104.5% YoY). In options structure, BU sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against ABVC sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
BU N/M vs ABVC N/M Fwd P/E
Growth & Margin Winner ABVC
Op Margin N/A vs 0.0% ยท YoY N/A vs +104.5%
Momentum & Technical Winner BU
1Y -9.1% vs -66.4% ยท 52W Pos 6% vs 10%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
BU US Equity
BU
Institutional Equity
$18.17
+0.46% 1D
Market Cap N/A
1M Return -14.04%
1Y Return -9.12%
Forward P/E N/M
Unified AI Score
53.5 / 100 HOLD
Tech 40.0 Fund 46.0 Flow 50.0 Mom 48.2
ABVC NASDAQ
ABVC BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$0.94
+3.3% 1D
Market Cap $24.5M
1M Return +2.41%
1Y Return -66.43%
Forward P/E N/M
Unified AI Score
39.0 / 100 SELL
Tech 32.0 Fund 37.0 Flow 50.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: BU -9.12% ABVC -66.43% Spread: +41.62 pp (BU Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
BU TTM Op. Margin: N/A ABVC TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BU vs ABVC. Trailing 12-month operating profitability (BU N/A vs ABVC 0.0%) and valuation multiples (BU N/M vs ABVC N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: BU (1) vs ABVC (7)
Institutional Metric BU ABVC Criterion Row Winner
Market Capitalization Scale N/A $24.5M Larger Scale ABVC
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth N/A +104.5% Higher Growth ABVC
Operating Margin (TTM) Profitability N/A 0.0% Higher Margin ABVC
Net Profit Margin Profitability N/A 0.0% Higher Margin ABVC
Return on Equity (ROE) Capital Efficiency N/A -52.7% Higher ROE ABVC
52-Week Range Position Momentum 6% ($17โ€“$39) 10% ($1โ€“$3) Stronger Trend ABVC
Beta / 30D Volatility Risk Regime 3.91ฮฒ ยท 97% Vol 1.34ฮฒ ยท 56% Vol Lower Realized Risk ABVC
Unified Institutional Score Composite Signal 53.5 / 100 (HOLD) 39.0 / 100 (SELL) Higher Composite BU

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full BU vs ABVC Buy Guide
BU UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live BU Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ABVC UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live ABVC Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither BU nor ABVC registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.